ASHLAND INC. (ASH) Form 8-K — Nov 3, 2026
Ashland reported preliminary Q4 FY2026 sales of $498 million, up 4% year over year, but swung to a net loss of $16 million (($0.36) diluted EPS from continuing operations) versus net income of $32 million in the prior-year quarter, driven by higher restructuring charges, an $18 million asset impairment, and a $13 million Argentina liquidation charge. On an adjusted basis results improved: Adjusted EBITDA rose 2% to $121 million and adjusted EPS excluding intangibles amortization rose to $1.12 from $1.08, with Life Sciences posting a record 35.6% EBITDA margin and Personal Care up 8% in sales.
Key figures
- Revenue
- 498000000
- Guidance
- FY2027 sales $1,905-$1,975 million; Adjusted EBITDA $405-$435 million; Ongoing FCF conversion >40% of Adjusted EBITDA
- Total Debt
- 1371000000
- Revenue Yoy
- 4% growth vs $478M prior-year quarter
- Total Assets
- 4527000000
- Cash Position
- 480000000
- Net debt
- $891 million
- Fy2026 sales
- $1.863 billion, up 2%
- Net leverage
- 2.3x
- Adjusted eps q4
- 1.12
- Fy2026 net income
- $4 million
- Adjusted ebitda q4
- $121 million, up 2% YoY
- Fy2026 adjusted ebitda
- $385 million vs $401 million prior year
- Adjusted ebitda margin q4
- 24.3%
- Ongoing free cash flow q4
- $74 million
- Q4 gaap loss vs prior income
- Net loss $16M vs net income $32M prior-year quarter
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.